BIOPHARMA
By
Can Johnson & Johnson’s $5B+ Immunology Bet Survive After Nipocalimab’s Rheumatoid Arthritis Setback?
Key Highlights: A Trial Disappointment, Not the EndgameJohnson & Johnson announced the discontinuation of nipocalimab development in rheumatoid…
Could Roche and Alnylam’s Phase III Trial of Zilebesiran Redefine Hypertension Care for 1.2 Billion Patients Worldwide?
Key Highlights Phase II Data Paves the WayThe KARDIA clinical program—spanning three Phase II trials—has provided the foundation…
Can AstraZeneca’s $50B US Investment and Eli Lilly’s $27B Manufacturing Expansion Reshape the Future of American Biopharma?
Key Highlights Virginia Bets Big on Biopharma GrowthVirginia lawmakers have approved significant development packages to draw two of…
Can Cambridge and A*STAR’s New AI Digital Twin Platform Transform $50Bn Pharma Manufacturing Efficiency Landscape?
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention Across Europe With Zero Infections in Phase 3 Trials?
Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and Sustained Efficacy in Over 2,600 Patients?
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…
